Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Operating Expenses (2016 - 2025)

Traws Pharma's Operating Expenses history spans 14 years, with the latest figure at $7.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $7.4 million for Q4 2025, up 38.13% from a year ago — trailing twelve months through Dec 2025 was $20.7 million (down 85.51% YoY), and the annual figure for FY2025 was $20.7 million, down 85.51%.
  • Operating Expenses for Q4 2025 was $7.4 million at Traws Pharma, up from $4.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $123.4 million in Q2 2024 to a low of $3.8 million in Q4 2021.
  • The 5-year median for Operating Expenses is $4.9 million (2021), against an average of $11.0 million.
  • The sharpest move saw Operating Expenses soared 2544.2% in 2024, then crashed 96.77% in 2025.
  • Year by year, Operating Expenses stood at $3.8 million in 2021, then skyrocketed by 51.61% to $5.8 million in 2022, then fell by 21.97% to $4.5 million in 2023, then grew by 18.06% to $5.3 million in 2024, then skyrocketed by 38.13% to $7.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $7.4 million, $4.1 million, and $4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.